

Gianluigi Savarese

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1308202/publications.pdf>

Version: 2024-02-01

199
papers

8,622
citations

76294

40
h-index

54882

84
g-index

206
all docs

206
docs citations

206
times ranked

9995
citing authors

#	ARTICLE	IF	CITATIONS
1	Global Public Health Burden of Heart Failure. <i>Cardiac Failure Review</i> , 2017, 03, 7.	1.2	1,731
2	Global burden of heart failure: a comprehensive and updated review of epidemiology. <i>Cardiovascular Research</i> , 2023, 118, 3272-3287.	1.8	517
3	Do Changes of 6-Minute Walk Distance Predict Clinical Events in Patients With Pulmonary Arterial Hypertension?. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1192-1201.	1.2	222
4	Gender differences in the effects of cardiovascular drugs. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017, 3, 163-182.	1.4	204
5	A comprehensive population-based characterization of heart failure with mid-range ejection fraction. <i>European Journal of Heart Failure</i> , 2017, 19, 1624-1634.	2.9	196
6	Benefits of Statins in Elderly Subjects Without Established Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2090-2099.	1.2	191
7	Molecular mechanism of endothelial and vascular aging: implications for cardiovascular disease. <i>European Heart Journal</i> , 2015, 36, 3392-3403.	1.0	183
8	Significance of Ischemic Heart Disease in Patients With Heart Failure and Preserved, Midrange, and Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	177
9	Patient profiling in heart failure for tailoring medical therapy. A consensus document of the <sc>Heart Failure Association of the European Society of Cardiology</sc>. <i>European Journal of Heart Failure</i> , 2021, 23, 872-881.	2.9	160
10	Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2018, 20, 1326-1334.	2.9	156
11	Heart failure with mid-range or mildly reduced ejection fraction. <i>Nature Reviews Cardiology</i> , 2022, 19, 100-116.	6.1	156
12	A Meta-Analysis Reporting Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients Without Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 61, 131-142.	1.2	154
13	Natriuretic Peptide-Guided Therapy in Chronic Heart Failure: A Meta-Analysis of 2,686 Patients in 12 Randomized Trials. <i>PLoS ONE</i> , 2013, 8, e58287.	1.1	141
14	The <sc>Heart Failure Association Atlas</sc>: <sc>Heart Failure Epidemiology and Management Statistics</sc> 2019. <i>European Journal of Heart Failure</i> , 2021, 23, 906-914.	2.9	130
15	Prevalence and Prognostic Implications of Longitudinal Ejection Fraction Change in Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 306-317.	1.9	125
16	Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. <i>European Heart Journal</i> , 2021, 42, 700-710.	1.0	117
17	Sex-Based Differences in Heart Failure Across the Ejection Fraction Spectrum. <i>JACC: Heart Failure</i> , 2019, 7, 505-515.	1.9	114
18	Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 180-188.	1.4	113

#	ARTICLE	IF	CITATIONS
19	The role of metabolic syndrome in heart failure. <i>European Heart Journal</i> , 2015, 36, 2630-2634.	1.0	96
20	Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis. <i>International Journal of Cardiology</i> , 2015, 181, 239-244.	0.8	88
21	Changes of Natriuretic Peptides Predict Hospital Admissions in Patients With Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2014, 2, 148-158.	1.9	84
22	Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 1378-1389.	2.9	83
23	Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (<sc>US</sc>, <sc>UK</sc> and Sweden). <i>European Journal of Heart Failure</i> , 2021, 23, 1499-1511.	2.9	80
24	Impact of Diabetes on Cardiac Sympathetic Innervation in Patients With Heart Failure. <i>Diabetes Care</i> , 2013, 36, 2395-2401.	4.3	79
25	Association Between Use of Primary-Prevention Implantable Cardioverter-Defibrillators and Mortality in Patients With Heart Failure. <i>Circulation</i> , 2019, 140, 1530-1539.	1.6	78
26	Safety and efficacy of ezetimibe: A meta-analysis. <i>International Journal of Cardiology</i> , 2015, 201, 247-252.	0.8	70
27	Temporal trends in incidence, causes, use of mechanical circulatory support and mortality in cardiogenic shock. <i>ESC Heart Failure</i> , 2021, 8, 1295-1303.	1.4	69
28	The Swedish Heart Failure Registry: a living, ongoing quality assurance and research in heart failure. <i>Uppsala Journal of Medical Sciences</i> , 2019, 124, 65-69.	0.4	68
29	Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2021, 23, 973-982.	2.9	65
30	Incidence, Predictors, and Outcome Associations of Dyskalemia in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 65-76.	1.9	62
31	Takotsubo Cardiomyopathy. <i>Heart Failure Clinics</i> , 2013, 9, 249-266.	1.0	61
32	The Prognostic Value of Normal Stress Cardiac Magnetic Resonance in Patients With Known or Suspected Coronary Artery Disease. <i>Circulation: Cardiovascular Imaging</i> , 2013, 6, 574-582.	1.3	61
33	Post-ischaemic silencing of p66^{Shc} reduces ischaemia/reperfusion brain injury and its expression correlates to clinical outcome in stroke. <i>European Heart Journal</i> , 2015, 36, 1590-1600.	1.0	61
34	Effects of Dipeptidyl Peptidase 4 Inhibitors and Sodium-Glucose Linked coTransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis. <i>International Journal of Cardiology</i> , 2016, 220, 595-601.	0.8	59
35	Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure. <i>JACC: Heart Failure</i> , 2016, 4, 870-880.	1.9	58
36	Effects of type 2 diabetes mellitus on coronary microvascular function and myocardial perfusion in patients without obstructive coronary artery disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1199-1206.	3.3	52

#	ARTICLE	IF	CITATIONS
37	Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality. <i>Circulation</i> , 2019, 139, 1458-1460.	1.6	49
38	A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction—insights from the ESC-HFA EORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2022, 24, 335-350.	2.9	49
39	Utilizing NT-proBNP for Eligibility and Enrichment in Trials in HFpEF, HFmrEF, and HFrEF. <i>JACC: Heart Failure</i> , 2018, 6, 246-256.	1.9	47
40	Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 171-180.	1.4	46
41	Association between renin-angiotensin-aldosterone system inhibitor use and COVID-19 hospitalization and death: a 1.4 million patient nationwide registry analysis. <i>European Journal of Heart Failure</i> , 2021, 23, 476-485.	2.9	46
42	Changes in serum uric acid levels and cardiovascular events: A meta-analysis. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2013, 23, 707-714.	1.1	45
43	Prevalence of, associations with, and prognostic role of anemia in heart failure across the ejection fraction spectrum. <i>International Journal of Cardiology</i> , 2020, 298, 59-65.	0.8	44
44	Expert Review on the Prognostic Role of Echocardiography after Acute Myocardial Infarction. <i>Journal of the American Society of Echocardiography</i> , 2017, 30, 431-443.e2.	1.2	43
45	Sex Differences in Heart Failure. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1065, 529-544.	0.8	43
46	Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2021, 23, 1844-1854.	2.9	42
47	Association of heart rate with mortality in sinus rhythm and atrial fibrillation in heart failure with preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2019, 21, 471-479.	2.9	41
48	Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 230-236.	1.4	39
49	Nurse-Led Heart Failure Clinics Are Associated With Reduced Mortality but Not Heart Failure Hospitalization. <i>Journal of the American Heart Association</i> , 2019, 8, e011737.	1.6	39
50	Association between renin-angiotensin system inhibitor use and mortality/morbidity in elderly patients with heart failure with reduced ejection fraction: a prospective propensity score-matched cohort study. <i>European Heart Journal</i> , 2018, 39, 4257-4265.	1.0	38
51	Haemodynamics, exercise capacity and clinical events in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2013, 42, 414-424.	3.1	37
52	Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care. <i>European Journal of Heart Failure</i> , 2021, 23, 1698-1707.	2.9	37
53	Use of evidence-based therapy in heart failure with reduced ejection fraction across age strata. <i>European Journal of Heart Failure</i> , 2022, 24, 1047-1062.	2.9	37
54	Reduction of albumin urinary excretion is associated with reduced cardiovascular events in hypertensive and/or diabetic patients. A meta-regression analysis of 32 randomized trials. <i>International Journal of Cardiology</i> , 2014, 172, 403-410.	0.8	36

#	ARTICLE	IF	CITATIONS
55	Insulin resistance is associated with impaired cardiac sympathetic innervation in patients with heart failure. <i>European Heart Journal Cardiovascular Imaging</i> , 2015, 16, 1148-1153.	0.5	36
56	Cardiac, renal, and metabolic effects of sodium-glucose cotransporter 2 inhibitors: a position paper from the European Society of Cardiology ad hoc task force on sodium-glucose cotransporter 2 inhibitors. <i>European Journal of Heart Failure</i> , 2021, 23, 1260-1275.	2.9	36
57	Sacubitril/valsartan eligibility and outcomes in the ESC/EORP/HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world. <i>European Journal of Heart Failure</i> , 2019, 21, 1383-1397.	2.9	35
58	Effects of atorvastatin and rosuvastatin on renal function: A meta-analysis. <i>International Journal of Cardiology</i> , 2013, 167, 2482-2489.	0.8	33
59	Reductions in N-Terminal Pro-Brain Natriuretic Peptide Levels Are Associated With Lower Mortality and Heart Failure Hospitalization Rates in Patients With Heart Failure With Mid-Range and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .	1.6	33
60	Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 1390-1398.	2.9	33
61	Use of sodium-glucose cotransporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2021, 23, 1012-1022.	2.9	33
62	Oral Anticoagulation Therapy in Heart Failure Patients in Sinus Rhythm: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2013, 8, e52952.	1.1	33
63	Association between dosing and combination use of medications and outcomes in heart failure with reduced ejection fraction: data from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2022, 24, 871-884.	2.9	33
64	Associations With and Prognostic and Discriminatory Role of N-Terminal Pro-B-Type Natriuretic Peptide in Heart Failure With Preserved Versus Mid-range Versus Reduced Ejection Fraction. <i>Journal of Cardiac Failure</i> , 2018, 24, 365-374.	0.7	32
65	COVID-19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2021, 23, 1806-1818.	2.9	32
66	Drug Layering in Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 775-783.	1.9	32
67	Enhanced age-dependent cerebrovascular dysfunction is mediated by adaptor protein p66Shc. <i>International Journal of Cardiology</i> , 2014, 175, 446-450.	0.8	31
68	Endothelial dysfunction in type 2 diabetic patients with normal coronary arteries. <i>International Journal of Cardiology</i> , 2013, 165, 67-71.	0.8	30
69	Age-dependent differences in clinical phenotype and prognosis in heart failure with mid-range ejection compared with heart failure with reduced or preserved ejection fraction. <i>Clinical Research in Cardiology</i> , 2019, 108, 1394-1405.	1.5	30
70	Comorbidities and cause-specific outcomes in heart failure across the ejection fraction spectrum: A blueprint for clinical trial design. <i>International Journal of Cardiology</i> , 2020, 313, 76-82.	0.8	30
71	Cardiac remodelling Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 927-943.	2.9	29
72	Effects of ranolazine in symptomatic patients with stable coronary artery disease. A systematic review and meta-analysis. <i>International Journal of Cardiology</i> , 2013, 169, 262-270.	0.8	27

#	ARTICLE	IF	CITATIONS
73	Reduced nitric oxide bioavailability mediates cerebroarterial dysfunction independent of cerebral amyloid angiopathy in a mouse model of Alzheimer's disease. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2017, 312, H232-H238.	1.5	27
74	Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 86-93.	1.4	27
75	Association between beta-blocker use and mortality/morbidity in older patients with heart failure with reduced ejection fraction. A propensity score-matched analysis from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 103-112.	2.9	27
76	Assessment of cardiac sympathetic activity by MIBG imaging in patients with heart failure: a clinical appraisal. <i>Heart</i> , 2011, 97, 1828-1833.	1.2	26
77	Left ventricular hypertrophy reduction and clinical events. A meta-regression analysis of 14 studies in 12,809 hypertensive patients. <i>International Journal of Cardiology</i> , 2013, 167, 2757-2764.	0.8	26
78	Lower socioeconomic status predicts higher mortality and morbidity in patients with heart failure. <i>Heart</i> , 2021, 107, 229-236.	1.2	26
79	An update on global epidemiology in heart failure. <i>European Heart Journal</i> , 2022, 43, 3005-3007.	1.0	26
80	Ticagrelor, but not clopidogrel, reduces arterial thrombosis via endothelial tissue factor suppression. <i>Cardiovascular Research</i> , 2017, 113, 61-69.	1.8	25
81	Reasons for and consequences of oral anticoagulant underuse in atrial fibrillation with heart failure. <i>Heart</i> , 2018, 104, 1093-1100.	1.2	25
82	Lipid management in rheumatoid arthritis: a position paper of the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 104-114.	1.4	25
83	Eligibility for mechanical circulatory support devices based on current and past randomised cardiogenic shock trials. <i>European Journal of Heart Failure</i> , 2021, 23, 1942-1951.	2.9	25
84	Prognostic role of myocardial single photon emission computed tomography in the elderly. <i>Journal of Nuclear Cardiology</i> , 2010, 17, 310-315.	1.4	23
85	The Impact of Social and Cultural Engagement and Dieting on Well-Being and Resilience in a Group of Residents in the Metropolitan Area of Naples. <i>Journal of Aging Research</i> , 2016, 2016, 1-11.	0.4	23
86	ACE-inhibitors versus angiotensin receptor blockers for prevention of events in cardiovascular patients without heart failure: A network meta-analysis. <i>International Journal of Cardiology</i> , 2016, 217, 128-134.	0.8	23
87	Ivabradine in Heart Failure. <i>Circulation: Heart Failure</i> , 2017, 10, .	1.6	23
88	The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 85-99.	1.4	23
89	Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms. <i>Cardiovascular Research</i> , 2022, 118, 2231-2252.	1.8	23
90	Non-cardiology vs. cardiology care of patients with heart failure and reduced ejection fraction is associated with lower use of guideline-based care and higher mortality: Observations from the Swedish Heart Failure Registry. <i>International Journal of Cardiology</i> , 2021, 343, 63-72.	0.8	23

#	ARTICLE	IF	CITATIONS
91	Patient profile and outcomes associated with follow-up in specialty vs. primary care in heart failure. ESC Heart Failure, 2022, 9, 822-833.	1.4	23
92	Prognostic role of transthoracic echocardiography in patients affected by heart failure and reduced ejection fraction. Heart Failure Reviews, 2015, 20, 305-316.	1.7	22
93	Cardiac remodelling—Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2022, 24, 944-958.	2.9	22
94	Efficacy and safety of glucagon-like peptide-1 agonists on macrovascular and microvascular events in type 2 diabetes mellitus: A meta-analysis. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 1081-1088.	1.1	21
95	Eligibility for Dapagliflozin and Empagliflozin in a Real-world Heart Failure Population. Journal of Cardiac Failure, 2022, 28, 1050-1062.	0.7	19
96	Myocardial perfusion scintigraphy and echocardiography for detecting coronary artery disease in hypertensive patients: a meta-analysis. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 2040-2049.	3.3	18
97	Prognostic impact of metabolic syndrome in patients with chronic heart failure: Data from GISSI-HF trial. International Journal of Cardiology, 2015, 178, 85-90.	0.8	18
98	Efficacy and safety of prolonged dual antiplatelet therapy: a meta-analysis of 15 randomized trials enrolling 85 265 patients. European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 2, 218-228.	1.4	18
99	Prognostic impact of Framingham heart failure criteria in heart failure with preserved ejection fraction. ESC Heart Failure, 2019, 6, 830-839.	1.4	18
100	Clinical and research implications of serum versus plasma potassium measurements. European Journal of Heart Failure, 2019, 21, 536-537.	2.9	18
101	N-terminal pro-b-type natriuretic peptide and left atrial function in patients with congestive heart failure and severely reduced ejection fraction. European Journal of Echocardiography, 2011, 12, 506-513.	2.3	17
102	Is ejection fraction in heart failure a limitation or an opportunity?. European Journal of Heart Failure, 2018, 20, 431-432.	2.9	17
103	Association Between β -Blockers and Outcomes in Heart Failure With Preserved Ejection Fraction: Current Insights From the SwedeHF Registry. Journal of Cardiac Failure, 2021, 27, 1165-1174.	0.7	17
104	Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 406-419.	1.4	17
105	Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. European Heart Journal, 2018, 39, 2274-2281.	1.0	16
106	Transient versus persistent improved ejection fraction in non-ischaemic dilated cardiomyopathy. European Journal of Heart Failure, 2022, 24, 1171-1179.	2.9	16
107	Deleterious role of endothelial lectin-like oxidized low-density lipoprotein receptor-1 in ischaemia/reperfusion cerebral injury. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 2233-2245.	2.4	15
108	N-terminal pro-B-type natriuretic peptide in chronic heart failure: The impact of sex across the ejection fraction spectrum. International Journal of Cardiology, 2019, 287, 66-72.	0.8	14

#	ARTICLE	IF	CITATIONS
109	The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid and diabetes trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 97-103.	1.4	14
110	Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial. <i>Journal of Cardiac Failure</i> , 2021, 27, 888-895.	0.7	14
111	Polypharmacy in Heart Failure with Reduced Ejection Fraction: Progress, Not Problem. <i>American Journal of Medicine</i> , 2021, 134, 1068-1070.	0.6	14
112	Non-insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials. <i>ESC Heart Failure</i> , 2020, 7, 3438-3451.	1.4	13
113	A registry-based algorithm to predict ejection fraction in patients with heart failure. <i>ESC Heart Failure</i> , 2020, 7, 2388-2397.	1.4	13
114	Eligibility for sacubitril/valsartan in heart failure across the ejection fraction spectrum: real-world data from the Swedish Heart Failure Registry. <i>Journal of Internal Medicine</i> , 2021, 289, 369-384.	2.7	13
115	Predictors of long-term outcome in heart failure with preserved ejection fraction: a follow-up from the <sc>KaRen</sc> study. <i>ESC Heart Failure</i> , 2021, 8, 4243-4254.	1.4	13
116	Prevalence and severity of asymptomatic coronary and carotid artery disease in patients with lower limbs arterial disease. <i>Atherosclerosis</i> , 2013, 228, 386-389.	0.4	12
117	Dietary omega-3 alpha-linolenic acid does not prevent venous thrombosis in mice. <i>Thrombosis and Haemostasis</i> , 2015, 113, 177-184.	1.8	12
118	Nuclear Assessment of Right Ventricle. <i>Echocardiography</i> , 2015, 32, S69-74.	0.3	12
119	Association Between β -Blocker Use and Mortality/Morbidity in Patients With Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction and Advanced Chronic Kidney Disease. <i>Circulation: Heart Failure</i> , 2020, 13, e007180.	1.6	12
120	Prevention of sudden death in heart failure with reduced ejection fraction: do we still need an implantable cardioverter-defibrillator for primary prevention?. <i>European Journal of Heart Failure</i> , 2022, 24, 1460-1466.	2.9	12
121	Sodium-glucose transporter inhibition in heart failure: from an unexpected side effect to a novel treatment possibility. <i>Diabetes Research and Clinical Practice</i> , 2021, 175, 108796.	1.1	11
122	Generalizability of randomized controlled trials in heart failure with reduced ejection fraction. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 761-769.	1.8	11
123	Sex-Related Differences in Dilated Cardiomyopathy with a Focus on Cardiac Dysfunction in Oncology. <i>Current Cardiology Reports</i> , 2020, 22, 102.	1.3	10
124	Potentially inappropriate prescriptions in heart failure with reduced ejection fraction: ESC position statement on heart failure with reduced ejection fraction-specific inappropriate prescribing. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 187-210.	1.4	10
125	Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease: a review in collaboration with the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 557-567.	1.4	10
126	Cardiac resynchronization therapy with or without defibrillator in patients with heart failure. <i>Europace</i> , 2022, 24, 48-57.	0.7	10

#	ARTICLE	IF	CITATIONS
127	Network meta-analysis of medical therapy efficacy in more than 90,000 patients with heart failure and reduced ejection fraction. <i>Journal of Internal Medicine</i> , 2022, 292, 333-349.	2.7	10
128	Predictors of primary prevention implantable cardioverter-defibrillator use in heart failure with reduced ejection fraction: impact of the predicted risk of sudden cardiac death and all-cause mortality. <i>European Journal of Heart Failure</i> , 2022, 24, 1212-1222.	2.9	10
129	Coronary computed tomography: current role and future perspectives for cardiovascular risk stratification. <i>European Heart Journal Cardiovascular Imaging</i> , 2012, 13, 453-458.	0.5	9
130	Ticagrelor, but not clopidogrel active metabolite, displays antithrombotic properties in the left atrial endocardium. <i>European Heart Journal</i> , 2017, 38, ehw578.	1.0	9
131	Digoxin use in contemporary heart failure with reduced ejection fraction: an analysis from the Swedish Heart Failure Registry. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 756-767.	1.4	9
132	Minimally Clinically Important Difference in Health Status Scores in Patients With HFrEF vs HFpEF. <i>JACC: Heart Failure</i> , 2022, 10, 651-661.	1.9	9
133	Catheter ablation for patients with atrial fibrillation and heart failure: insights from the Swedish Heart Failure Registry. <i>European Journal of Heart Failure</i> , 2022, 24, 1636-1646.	2.9	9
134	Tai Chi and Qigong Practices for Chronic Heart Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Evidence-based Complementary and Alternative Medicine</i> , 2020, 2020, 1-15.	0.5	8
135	Reduction of C-reactive protein is not associated with reduced cardiovascular risk and mortality in patients treated with statins. A meta-analysis of 22 randomized trials. <i>International Journal of Cardiology</i> , 2014, 177, 152-160.	0.8	7
136	Comparative associations between angiotensin converting enzyme inhibitors, angiotensin receptor blockers and their combination, and outcomes in patients with heart failure and reduced ejection fraction. <i>International Journal of Cardiology</i> , 2015, 199, 415-423.	0.8	7
137	Cardiovascular pharmacotherapy in older people: challenges posed by cardiovascular drug prescription in the elderly. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 277-279.	1.4	7
138	Use of Renin-Angiotensin-Aldosterone System Inhibitors in Older Patients with Heart Failure and Reduced Ejection Fraction. <i>Cardiac Failure Review</i> , 2019, 5, 70-73.	1.2	7
139	Implementation science and potential for screening in heart failure. <i>European Heart Journal</i> , 2022, 43, 413-415.	1.0	7
140	Dropping aspirin in patients with atrial fibrillation undergoing percutaneous coronary intervention: a jump with a weak parachute?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 55-56.	1.4	6
141	The interaction between dapagliflozin and blood pressure in heart failure: new evidence dissipating concerns. <i>European Heart Journal</i> , 2020, 41, 3419-3420.	1.0	6
142	Inter-twinning relationship between heart failure and atrial fibrillation. <i>Heart</i> , 2020, 106, 1125-1126.	1.2	6
143	Risk of sudden cardiac death in New York Heart Association class I patients with dilated cardiomyopathy: A competing risk analysis. <i>International Journal of Cardiology</i> , 2020, 307, 75-81.	0.8	6
144	Subgroup analyses in randomized clinical trials: value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, , .	1.4	6

#	ARTICLE	IF	CITATIONS
145	Combining New Classes of Drugs for HFrEF: from Trials to Clinical Practice. <i>European Journal of Internal Medicine</i> , 2021, 90, 10-15.	1.0	6
146	Education and certification on heart failure of the <sc>H</sc>eart <sc>F</sc>ailure <sc>A</sc>ssociation of the <sc>E</sc>uropean <sc>S</sc>ociety of <sc>C</sc>ardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 249-253.	2.9	6
147	Echocardiographic Biventricular Coupling Index to Predict Precapillary Pulmonary Hypertension. <i>Journal of the American Society of Echocardiography</i> , 2022, 35, 715-726.	1.2	6
148	Evidence-based Therapy in Older Patients with Heart Failure with Reduced Ejection Fraction. <i>Cardiac Failure Review</i> , 2022, 8, e16.	1.2	6
149	Cardiac magnetic resonance for the assessment of myocardial viability. <i>Journal of Cardiovascular Medicine</i> , 2013, 14, 862-869.	0.6	5
150	The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trials. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 453-459.	1.4	5
151	Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGONâ€HF trial. <i>ESC Heart Failure</i> , 2022, 9, 164-177.	1.4	5
152	Apparent Treatment-Resistant Hypertension Across the Spectrum of Heart Failure Phenotypes in the SwedishâHF Registry. <i>JACC: Heart Failure</i> , 2022, 10, 380-392.	1.9	5
153	From mid-range to mildly reduced ejection fraction heart failure: A call to treat. <i>European Journal of Internal Medicine</i> , 2022, 103, 29-35.	1.0	5
154	Changes in natriuretic peptides after acute hospital presentation for heart failure with preserved ejection fraction: A feasible surrogate trial endpoint? A report from the prospective Karen study. <i>International Journal of Cardiology</i> , 2017, 226, 65-70.	0.8	4
155	Use of loop diuretics in chronic heart failure: do we adhere to the <sc>Hippocratican</sc> principle â€do no harmâ€™?. <i>European Journal of Heart Failure</i> , 2021, 23, 1068-1075.	2.9	4
156	Challenges in cardiovascular pharmacogenomics implementation: a viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 100-103.	1.4	4
157	Prognosis for patients with heart failure and reduced ejection fraction with and without diabetes: A 7-year nationwide veteran administration analysis. <i>International Journal of Cardiology</i> , 2022, 346, 30-34.	0.8	4
158	Biomarker changes as surrogate endpoints in earlyâ€phase trials in heart failure with reduced ejection fraction. <i>ESC Heart Failure</i> , 2022, 9, 2107-2118.	1.4	4
159	Reply. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2303.	1.2	3
160	Digoxin: beneficial or harmful?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017, 3, 127-128.	1.4	3
161	ASSOCIATION BETWEEN SERUM POTASSIUM LEVEL AND OUTCOMES IN HEART FAILURE WITH REDUCED EJECTION FRACTION: A COHORT STUDY FROM THE SWEDISH HEART FAILURE REGISTRY. <i>Journal of the American College of Cardiology</i> , 2017, 69, 678.	1.2	3
162	Implantable cardioverter defibrillator to prevent sudden cardiac death in a patient with systemic sclerosis: A clinical case. <i>Journal of Cardiology Cases</i> , 2012, 5, e166-e170.	0.2	2

#	ARTICLE	IF	CITATIONS
163	Incretin-based therapy for type 2 diabetes: A real class effect?. International Journal of Cardiology, 2017, 227, 141-142.	0.8	2
164	Association between heart failure and cancer: is gender the answer?. European Journal of Heart Failure, 2021, 23, 1722-1724.	2.9	2
165	New trial evidence and guidelines on heart failure: news from the European Society of Cardiology Congress 2021. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e89-e90.	1.4	2
166	Comparison of linear versus cubic assessment of left atrial size in the prediction of atrial fibrillation development in hypertrophic cardiomyopathy. International Journal of Cardiology, 2016, 212, 198-200.	0.8	1
167	Reply to: Ezetimibe: A real effect?. International Journal of Cardiology, 2016, 209, 337-338.	0.8	1
168	Ticagrelor versus prasugrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: An unresolved issue. International Journal of Cardiology, 2017, 249, 77-78.	0.8	1
169	Response by Schrage et al to Letter Regarding Article, "Association Between Use of Primary-Prevention Implantable Cardioverter-Defibrillators and Mortality in Patients With Heart Failure: A Prospective Propensity Score-Matched Analysis From the Swedish Heart Failure Registry". Circulation, 2020, 141, e648-e649.	1.6	1
170	The tight tie of MAG versus SAG in CABG. International Journal of Cardiology, 2021, 323, 26.	0.8	1
171	Best of European Journal of Heart Failure at the ESC/HFA Heart Failure Congress 2021. European Journal of Heart Failure, 2021, 23, 1424-1427.	2.9	1
172	Open Up your Science in EHI Open. European Heart Journal Open, 2021, 1, .	0.9	1
173	PharmaPulse: new trial evidence from the HFA/ESC Heart Failure Congress 2021. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e88.	1.4	1
174	Up-titrating angiotensin-converting enzyme inhibitors in heart failure: evidence and challenges. European Journal of Heart Failure, 2018, 20, 370-372.	2.9	1
175	Most Common Causes of Hospitalization Associated with Inpatient Mortality in the United States Between 2005-2018. American Journal of the Medical Sciences, 2022, 363, 459-461.	0.4	1
176	An update on diabetes spectrum in heart failure: current evidence and potential therapeutic applications. Heart Failure Reviews, 2022, , 1.	1.7	1
177	Endogenous sex hormones are associated with blood pressure change and hypertension incidence in postmenopausal women. Clinical Lipidology, 2012, 7, 617-620.	0.4	0
178	Insulin resistance is associated with impaired cardiac sympathetic innervation in patients with heart failure. European Heart Journal, 2013, 34, P5728-P5728.	1.0	0
179	Vitamin D and parathyroid hormone. Journal of Cardiovascular Medicine, 2015, 16, 71.	0.6	0
180	Optimizing patient selection in heart failure trials: the role of NT-proBNP. European Heart Journal, 2018, 39, .	1.0	0

#	ARTICLE	IF	CITATIONS
181	P2494 Deleterious role of endothelial lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) in ischemia/reperfusion-induced cerebral injury. <i>European Heart Journal</i> , 2018, 39, .	1.0	0
182	Reply. <i>JACC: Heart Failure</i> , 2019, 7, 533-534.	1.9	0
183	The GUIDE heart failure risk prediction model: another fish in the sea?. <i>European Journal of Heart Failure</i> , 2019, 21, 779-780.	2.9	0
184	P3544 Role of cardiovascular comorbidities in heart failure across the ejection fraction spectrum. <i>European Heart Journal</i> , 2019, 40, .	1.0	0
185	PARAGON-HF - considerations for potential use of sacubitril-valsartan in real-world heart failure with mildly reduced ejection fraction. <i>Journal of Cardiac Failure</i> , 2019, 25, 1012-1013.	0.7	0
186	Iron deficiency in heart failure. <i>International Journal of Cardiology</i> , 2020, 299, 207.	0.8	0
187	SO057 BETA-BLOCKERS ARE ASSOCIATED WITH REDUCED MORTALITY IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION AND ADVANCED CHRONIC KIDNEY DISEASE: COHORT STUDY. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	0
188	P0771 STOPPING MINERALOCORTICOID RECEPTOR ANTAGONISTS AFTER HYPERKALEMIA AND RISK OF ADVERSE OUTCOMES IN PATIENTS WITH HEART FAILURE. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	0
189	Sex-related differences in therapeutic response to mineralocorticoid receptor antagonists in heart failure: summarizing trial evidence. <i>European Journal of Heart Failure</i> , 2020, 22, 845-847.	2.9	0
190	Sodium-glucose co-transporter 2 inhibitors in heart failure. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, e9-e10.	1.4	0
191	Use of loop diuretics in chronic heart failure: do we adhere to the Hippocratic principle 'œdo no harm'? <i>European Journal of Heart Failure</i> , 2021, .	2.9	0
192	Methodological issues in meta-analyses of real-world clinical data to infer causality. <i>International Journal of Cardiology</i> , 2021, 345, 107-108.	0.8	0
193	Abstract 12849: Changes in N-terminal Pro Brain Natriuretic Peptide Levels Predicts Mortality and Heart Failure Hospitalization in Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation</i> , 2015, 132, .	1.6	0
194	Behavioural Interventions to Reduce Cardiovascular Risk: Where Do We Stand?. <i>European Cardiology Review</i> , 2019, 14, 139-140.	0.7	0
195	New evidence from the scientific sessions 2020 of the American Heart Association. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, e1-e1.	1.4	0
196	Association between use of beta-blockers and mortality/morbidity in patients with heart failure with reduced, midrange or preserved ejection fraction and advanced chronic kidney disease. <i>European Heart Journal</i> , 2020, 41, .	1.0	0
197	297 Echocardiographic biventricular coupling index to predict pre-capillary pulmonary hypertension. <i>European Heart Journal Supplements</i> , 2021, 23, .	0.0	0
198	New Trial Evidence on Heart Failure: Highlights from the European Society of Cardiology Congress 2021. <i>European Cardiology Review</i> , 0, 17, .	0.7	0

#	ARTICLE	IF	CITATIONS
199	Catheter ablation for patients with atrial fibrillation and heart failure: insights from the swedish heart failure registry. Europace, 2022, 24, .	0.7	0